{"entity":{"id":"rc118-adc","kind":"drug","name":"RC118-ADC","aka":["RC118 for injection"],"tldr":"RC118-ADC is an experimental antibody-drug conjugate from RemeGen in phase 2 trials, aimed at Claudin 18.2.","summary":"RC118-ADC (RC118) is an antibody-drug conjugate developed by RemeGen. Its target is Claudin 18.2 (the sponsor names Claudin 18.2). The sponsor states: An antibody-drug conjugate combining a Claudin 18.2-targeting antibody with a microtubule inhibitor payload. ClinicalTrials.gov describes the intervention as: RC118 for injection is a novel antibody-drug conjugate, with a Claudin 18.2-targeting antibody and a microtube inhibitor. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial. The largest, NCT05205850, plans to enrol 135 participants with primary completion was scheduled for 2025-09-30 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of RC118-ADC","url":"https://clinicaltrials.gov/search?intr=RC118"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["cldn18-2"],"drugs":[],"companies":["remegen"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06038396","nct05205850"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"code":"RC118","modality":"ADC","mechanism":"An antibody-drug conjugate combining a Claudin 18.2-targeting antibody with a microtubule inhibitor payload.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/rc118-adc/","neighbours":{"target":[{"id":"cldn18-2","kind":"target","name":"Claudin 18.2","route":"/targets/cldn18-2/"}],"company":[{"id":"remegen","kind":"company","name":"RemeGen","route":"/companies/remegen/"}],"trial":[{"id":"nct05205850","kind":"trial","name":"A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors","route":"/trials/nct05205850/"},{"id":"nct06038396","kind":"trial","name":"A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors","route":"/trials/nct06038396/"}]}}